DEBRA HUDSON: Open Payments
NPI 1962642355 · PLANO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,808 in 80 payments from 16 companies in 2025. Trend: 2023 $1,432 · 2024 $1,292 · 2025 $1,808
Food & beverage: $1,808
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 22 | $601 |
| Janssen Biotech, Inc. | 9 | $205 |
| Aimmune Therapeutics, Inc. | 11 | $196 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $158 |
| Phathom Pharmaceuticals, Inc. | 6 | $132 |
| GENZYME CORPORATION | 4 | $96 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $84 |
| Madrigal Pharmaceuticals | 2 | $67 |
| Celltrion USA Inc. | 3 | $64 |
| Regeneron Healthcare Solutions, Inc. | 2 | $45 |
Products named: TREMFYA, SKYRIZI, RINVOQ, VOQUEZNA, ENTYVIO, ZENPEP, DUPIXENT, LINZESS.
Industry payments across TX — which companies pay providers there.
